Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration

20242 citationsJournal Articlegold Open Access

Authors

Masashi Okawa · Kagoshima University

Munekazu Yamakuchi · Kagoshima University

Bibek Aryal · Kagoshima University

Kazunori Takenouchi · Kagoshima University

Drew N. Maywar · Rochester Institute of Technology

Shingo Yamada · Shino-Test Corporation

Keiichi Inoue ·

Abstract

The VEGF-A121 isoform has been uniquely demonstrated as a clear marker of bevacizumab therapy in both plasma and serum, motivating further research on pursuing these isoforms as biomarkers in cancer care.

Topics & Keywords

Angiogenesis and VEGF in Cancer Cancer Treatment and Pharmacology Vascular Tumors and Angiosarcomas

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PLoS ONE

Volume 19, Issue 12, pp. e0316035-e0316035

DOI: 10.1371/journal.pone.0316035

Field-Weighted Citation Impact: 0.47